Information  X 
Enter a valid email address

Physiomics PLC (PYC)

  Print   

Tuesday 23 November, 2021

Physiomics PLC

Result of AGM

RNS Number : 3189T
Physiomics PLC
23 November 2021
 

23 November 2021 

Physiomics plc

("Physiomics" or "the Company")

 

Result of AGM

 

Physiomics plc (AIM: PYC), an oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions , is pleased to announce that all resolutions put to shareholders at the Company's Annual General Meeting, held earlier today at the Company's offices in Oxford, were duly passed.

 

 

Enquiries:

 

Physiomics plc

Dr Jim Millen, CEO

+44 (0)1865 784 980

 

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

 

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0)20 3764 2341

 

Notes to Editor

 

About Physiomics

 

Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions. The Company's Virtual Tumour™ technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Physiomics' technologies have been confirmed by over 80 projects, involving over 40 targets and 70 drugs, and has worked with clients such as Merck KGaA, Astellas, Merck & Co and Bicycle Therapeutics.

 

For more information please visit:

 

www.physiomics.co.uk  

www.twitter.com/Physiomics  

www.linkedin.com/company/physiomics-plc/  

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGZZMZMKFKGMZM

a d v e r t i s e m e n t